US FDA warns consumers over copycats of Bausch + Lomb eye drops
Send a link to a friend
[February 01, 2024]
(Reuters) - The U.S. Food and Drug Administration (FDA) on
Wednesday warned consumers not to use unapproved eye drops that closely
resemble Bausch + Lomb's Lumify product for redness relief.
The copycat products, called South Moon, Rebright and FivFivGo, could be
easily mistaken for Lumify, the FDA said.
"We're working closely with the FDA and our authorized retail partners
to help protect individuals from copycat products," Bausch + Lomb said.
Testing of South Moon showed it was contaminated by bacteria that could
result in antibiotic-resistant infection.
Although Rebright tested negative for contamination, the FDA said it
does not recommend consumers use the product. The agency was unable to
obtain samples of FivFivGo.
The FDA said it was not notified of any adverse events from the specific
products, but has received reports related to possibly fake Lumify,
including product quality concerns, eye irritation, pain and infection.
[to top of second column]
|
Signage is seen outside of the Food and Drug Administration (FDA)
headquarters in White Oak, Maryland, U.S., August 29, 2020.
REUTERS/Andrew Kelly/File Photo
Lumify is an over-the-counter eye
drop used to relieve redness in the eye due to minor irritation.
The agency says it is unable to verify the origin of the copycat
products, and is continuing its investigation. South Moon is labeled
as manufactured by Shantou Cross-border Premium Products E-Commerce
Co Ltd, in China.
Reuters could not immediately contact Shantou Cross-border Premium
Products E-Commerce.
(Reporting by Unnamalai L and Puyaan Singh in Bengaluru; Editing by
Krishna Chandra Eluri)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |